Workflow
退市
icon
Search documents
互联网及教育行业行业更新:基本面仍是支撑估值重要因素,看好服务平台机会
BOCOM International· 2025-05-07 13:42
交银国际研究 行业更新 互联网及教育行业 基本面仍是支撑估值重要因素,看好服务平台机会 2025 年 5 月 7 日 行业与大盘一年趋势图 资料来源 : FactSet 5/24 9/24 1/25 5/25 -20% -15% -10% -5% 0% 5% 10% 15% 20% 25% 30% 35% 行业表现 MSCI中国指数 谷馨瑜, CPA connie.gu@bocomgroup.com (86) 10 8393 5330 孙梦琪 mengqi.sun@bocomgroup.com (86) 10 8393 5333 赵丽, CFA zhao.li@bocomgroup.com (86) 10 8393 5332 蔡涵 hanna.cai@bocomgroup.com (86) 10 8393 5334 此报告最后部分的分析师披露、商业关系披露和免责声明为报告的一部分,必须阅读。 下载本公司之研究报告,可从彭博信息:BOCM 或 https://research.bocomgroup.com 我们覆盖的互联网及教育公司股价表现:2025 年 4 月,云音乐+22%/有道 +17%/新东方+5%/阅 ...
锦州港财务造假屡犯不改 造假多年被审计机构大华无视?
Xin Lang Zheng Quan· 2025-05-07 10:00
令人震惊的是,锦州港在2024年11月首次被证监会立案调查并处罚后,仍持续造假。值得注意的是,公 司18年至23年年报审计机构均为大华会计事务所,但造假似乎被其无视,多年出具无保留的审计意见类 型。 曾系统性财务造假被立案,虚增利润超1.7亿元 锦州港的财务造假行为最早可追溯至2018年。根据中国证监会2024年6月披露的《行政处罚及市场禁入 事先知书》,公司为"做大收入和利润、满足银行贷款需求",通过无商业实质的虚假贸易业务,系统性 虚增营业收入、营业成本和利润总额。具体来看: 造假规模:2018年至2021年累计虚增营业收入86.24亿元,虚增利润总额1.79亿元。其中,2018年虚增利 润2070.9万元,2019年3899.9万元,2020年4415.7万元,2021年7511.4万元。 造假手段:通过子公司锦国投(大连)发展有限公司控制上下游供应商及客户的资金流转,形成闭环资 金池。例如,采购资金经大连和境等五家供应商流入锦国投资金池,再通过上海盛辙、舟山丰聚益尚等 公司回流至锦州港,制造虚假贸易流水。 责任认定:时任董事长徐健、副董事长兼总经理刘辉被认定为直接负责的主管人员,财务总监李挺等高 管为 ...
这家市值200亿的ST公司被立案调查,投资者咋办?
Guo Ji Jin Rong Bao· 2025-05-07 09:25
山东新潮能源股份有限公司(简称ST新潮,600777.SH),这家市值超200亿(截至5月7日为218.3亿)公司的股民,这几天有点儿焦虑,甚至 恐慌了。 本来坐山观虎斗、鹬蚌相争的渔翁得利之局,突然横生变数。此前,内蒙古伊泰煤炭股份有限公司(900948.SH,下称"伊泰B股")和浙江金帝 石油勘探开发有限公司(下称"金帝石油"),都向ST新潮股东发出部分要约收购。 制图:佘诗婕 7日,ST新潮公告称,6日收到中国证监会的《立案告知书》,原因是未按规定披露2024年年报。 有意思的是,尽管被中国证监会立案调查,ST新潮却公告称,"公司将积极配合中国证监会的相关工作,并严格按照规定及监管要求履行信息 披露义务。目前公司经营情况正常。" 而对ST新潮的投资者来说,现在面临的风险和不确定性就大多了。 根据《上市公司信息披露管理办法》,ST新潮股票自5月6日起停牌。若停牌后两个月内仍无法披露年报,将被实施退市风险警示(*ST);若 此后两个月仍未披露,可能被终止上市。 也就是说,ST新潮的股民未来一段时间内可能面临股票退市的风险。 有猜测称,公司年报难产可能与更换审计机构有关。 2024年,ST新潮的原审计机构中兴 ...
*ST声迅1年1期亏损 2020年上市西部证券保荐已两募资
Zhong Guo Jing Ji Wang· 2025-05-07 06:52
*ST声迅2025年第一季度报告显示,公司首季实现营业收入0.19亿元,同比下降1.35%;归属于上市公司 股东的净利润-0.14亿元,上年同期为-0.11亿元;归属于上市公司股东的扣除非经常性损益的净利 润-0.15亿元,上年同期为-0.11亿元;经营活动产生的现金流量净额为-0.21亿元,上年同期为-0.18亿 元。 中国经济网北京5月7日讯*ST声迅(003004)(003004.SZ)近日披露的2024年年度报告显示,公司去年实 现营业收入3.02亿元,同比增长7.85%;归属于上市公司股东的净利润-0.51亿元,上年同期为0.25亿 元;归属于上市公司股东的扣除非经常性损益的净利润-0.55亿元,上年同期为0.21亿元;经营活动产生 的现金流量净额为-0.56亿元,上年同期为-0.01亿元。 | | 2024年 | 2023 年 | 本年比上年增减 | 2022 年 | | --- | --- | --- | --- | --- | | 营业收入(元) | 301,739,128.07 | 279,777,844.68 | 7.85% | 317,255,660.87 | | 归属于上市公司股东的净 ...
新股发行及今日交易提示-20250507
HWABAO SECURITIES· 2025-05-07 06:25
| 新股发行及今日交易提示 | 2025/5/7 | 星期三 | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 2025/5/7 | 新股发行 | 证券代码 | 证券简称 | 发行价格 | | | | | 787755 | 汉邦科技 | 22.77 | 2025/5/7 | 内地市场权益提示 | | | | | 类别 | 证券代码 | 证券简称 | 权益日期 | 最新公告链接 | https://www.cninfo.com.cn/new/disclosure/detail?stockCode=600777&announcementId=122337 | 要约申报期1:2025年4月8日至2025年5月7日 | | | 5830&orgId=gssh0600777&announcementTime=2025 | -04-29 | 要约收购 | 600777 | ST新潮 | https://www.cninfo.com.cn/new/disclosure/detail?stockCode=600777&announcementId= ...
中概退市风险步步逼近!美国国会特别委员会再就中概退市致信美SEC,如何应对?
贝塔投资智库· 2025-05-07 03:38
《外国公司问责法》由特朗普于2020年12月18日签署生效 ,旨在要求在美国上市的外国公司满足美国公众公司会计监督委员会(PCAOB)的审 计标准,这一事件为后续诸多中概股 "主动退市求变,而非坐等被驱离" 埋下伏笔。 瑞银驻华盛顿的高级政府事务顾问约翰・诺兰(John Nolan)称 , 众议员约翰・穆尔纳凭借其主席身份拥有影响力和传票权力,但他没有任何直 接立法权。 华盛顿方面的观点是,虽然这个问题上没有形成广泛的民意浪潮,但如今任何涉及对中国采取强硬立场的事情,通常都会在一定程度上获得两党 的广泛支持。这封信由来自参众两院的两党议员广泛联署。 因此,尽管这封信可能不会产生太大影响,但特朗普政府仍存在采取更广泛退市行动的实际风险。 更大的问题在于,更广泛的退市举措对美国政府和财政部而言是否具有时效性和战略价值?鉴于中美之间的紧张关系,以及美国政府希望找到潜 在的施压点,正如美国财政部长斯科特・贝森特(Scott Bessent)最近所说:"…… 一切都在谈判桌上。" 2022 年 8 月,包括中国石油、中海油、华能国际、中国人寿在内的多家国有企业相继从美股退市。 瑞银称: "四年后的今天,我们似乎回到了一 ...
天茂集团年报“难产”触发退市警报 遭证监会立案调查
Xin Lang Zheng Quan· 2025-05-07 02:57
登录新浪财经APP 搜索【信披】查看更多考评等级 天茂集团因未能在法定期限内披露2024年年度报告及2025年第一季度报告,引发深交所停牌及证监会立 案调查,这一事件背后折射出多重问题,涉及公司治理、财务风险及监管合规等层面。 天茂集团原定于2025年4月29日披露定期报告,但因"部分信息需进一步核实"导致年报编制未完成,最 终未能在4月30日法定期限内披露。 根据深交所规则,公司股票自5月6日起停牌,若停牌两个月内仍无法披露年报,将被实施退市风险警示 (ST);若此后两个月内仍无法披露符合要求的年报,则可能被终止上市。 停牌次日(5月6日),公司因涉嫌未按期披露定期报告被证监会立案调查,进一步加剧退市风险。 天茂集团近年来持续亏损,2023年亏损6.52亿元,2024年预计亏损5亿至7.5亿元,主要受子公司国华人 寿拖累。 若公司未能在停牌后四个月内完成年报披露,将触发终止上市程序。当前股价已从年初高位下跌超 40%,停牌前报2.74元,市值缩水至135亿元,投资者信心严重受挫。 证监会立案调查可能进一步揭示公司信息披露违规细节,若查实财务造假或恶意拖延,公司将面临罚 款、高管追责等处罚,甚至加速退市进程。 ...
昔日“亚洲铝王”中国忠旺将退市 曾A股借壳未果
Core Viewpoint - China Zhongwang Holdings Limited, once known as the "Asian Aluminum King," announced its delisting from the Hong Kong Stock Exchange, with the last trading day set for April 12, 2023, marking a significant decline from its peak as a major player in the aluminum industry [2][3]. Company Overview - China Zhongwang was established in 1993 and is headquartered in Liaoyang, Liaoning Province, primarily engaged in the research, production, and sales of industrial aluminum processing products [3]. - The company has developed a diversified business model focusing on three core areas: industrial aluminum extrusion, deep processing, and aluminum rolling [3]. Historical Context - The company went public on May 8, 2009, and was recognized as the largest IPO globally following the 2008 financial crisis [2]. - In 2017, China Zhongwang made strategic acquisitions, including German high-end aluminum extrusion company Una Aluminum and Australian super yacht manufacturer Silver Yachts, to enhance its global presence [3]. Legal and Financial Challenges - In July 2019, China Zhongwang and several defendants were indicted by a grand jury in Los Angeles on 24 counts, leading to concerns about the company's operational and financial stability [4]. - The company faced significant operational difficulties, with its subsidiaries reporting severe financial losses and seeking bankruptcy restructuring in 2022 [5][6]. Restructuring Efforts - In September 2022, 14 subsidiaries of China Zhongwang filed for bankruptcy restructuring, with the court approving a substantial merger of 253 related companies to protect creditor rights [6]. - The deadline for submitting a restructuring plan was extended to June 20, 2023, indicating ongoing efforts to stabilize the company's financial situation [6]. Failed Listing Attempts - China Zhongwang attempted to spin off its subsidiary for a backdoor listing on the A-share market through China Real Estate Group but was unsuccessful in multiple attempts, leading to the eventual termination of these plans [7][8].
中航产融年报“难产”退市申请获受理 负债率85.13%拟40.7亿清仓两公司股票
Chang Jiang Shang Bao· 2025-05-06 23:28
Core Viewpoint - China Aviation Industry Fund (中航产融) is selling assets to recover funds as it is in the process of delisting from the stock market due to significant operational uncertainties and expected financial losses [1][2][7]. Group 1: Asset Sale Details - The company plans to transfer 160 million shares of AVIC Xi'an Aircraft Industry Group (中航西飞) and 22.68 million shares of AVIC Aircraft (中航机载) to its controlling shareholder, AVIC (中国航空工业集团), for a total price of approximately 4.067 billion yuan [1][4]. - The share transfer represents 5.76% of AVIC Xi'an's total shares and 0.47% of AVIC Aircraft's total shares [4]. - The transfer price is based on the average weighted price of the shares over the previous 30 trading days, with AVIC Xi'an priced at 23.81 yuan per share and AVIC Aircraft at 11.19 yuan per share [4]. Group 2: Financial Performance and Future Plans - As of September 2024, the company's total assets amounted to 442.393 billion yuan, with a debt-to-asset ratio of 85.13% [3][6]. - The company anticipates a net loss of approximately 48 million yuan for 2024, marking its first loss since 2006, with a projected net loss of 189 million yuan after excluding non-recurring items [2][5]. - The company is actively pursuing a voluntary delisting from the A-share market, with the Shanghai Stock Exchange having accepted its application for termination of listing [2][7][8]. Group 3: Legal Issues - The company is facing a lawsuit from China Life Insurance (中国人寿) regarding a share buyback dispute, with the total claim amounting to approximately 2.71 billion yuan [9][10].
海南双成药业股份有限公司关于参加“2024 年度海南辖区上市公司业绩 说明会暨投资者集体接待日”的公告
Group 1 - The company will participate in the "2024 Annual Performance Briefing and Investor Reception Day" on May 13, 2025, to enhance communication with investors regarding its annual report and other key topics [1] - The company has received marketing authorization from the Therapeutic Goods Administration (TGA) in Australia for its injectable drug Bivalirudin, which is indicated as an anticoagulant for high-risk acute coronary syndrome patients [3][4] - The injectable Bivalirudin has previously received approvals from various regulatory bodies, including the FDA in the United States and the Saudi Arabian SFDA [5] Group 2 - The company's stock has experienced abnormal trading fluctuations, with a cumulative price deviation exceeding 12% over two consecutive trading days [9] - The company has confirmed that there are no undisclosed significant matters that could affect its stock price, and it has conducted a thorough review of its recent trading activity [10][11] - The company has been placed under a delisting risk warning due to negative financial results, with the lowest of its audited profit total, net profit, and net profit after non-recurring gains and losses being negative, and revenue below 300 million [12]